07:00 , May 23, 2016 |  BioCentury  |  Strategy

Two heads are better

With Gleevec imatinib off patent, flagging ophthalmics sales and at least one slower than expected launch, Novartis AG is consolidating operations at the top to cut costs, while also splitting its R&D into two buckets:...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Azarga brinzolamide/timolol regulatory update

EMEA approved an MAA from Alcon for Azarga brinzolamid/timolol to treat elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension in adults for whom monotherapy is insufficient. The brinzolamid/timolol eye drop combines 10...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

Azarga brinzolamide/timolol regulatory update

EMEA's CHMP recommended approval of an MAA from Alcon for Azarga brinzolamid/timolol to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. Azarga is...